Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SGK1 | O00141 | 6/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755040 | 0.92 | LMNA (0.46) | SMN1; SMN2LMNAIDH1MEN1KMT2A | |
| SCHEMBL23846572 | 0.92 | IDH1 (0.44) | SMN1; SMN2LMNAHPGDIDH1MEN1 | |
| SCHEMBL25757152 | 0.81 | IDH1 (0.48) | SMN1; SMN2LMNAHPGDIDH1MEN1 | |
| SCHEMBL25755058 | 0.80 | LMNA (0.52) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL23846318 | 0.80 | LMNA (0.52) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL25755054 | 0.80 | MAPT (0.52) | SMN1; SMN2LMNAHPGDIDH1MEN1 | |
| SCHEMBL25755048 | 0.80 | IDH1 (0.47) | SMN1; SMN2LMNAHPGDIDH1MEN1 | |
| SCHEMBL25755022 | 0.79 | KMT2A (0.59) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL25755134 | 0.78 | LMNA (0.50) | SMN1; SMN2LMNAHPGDMEN1KMT2A | |
| SCHEMBL25755128 | 0.78 | MAPT (0.51) | SMN1; SMN2LMNAHPGDIDH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | SMN1; SMN2 405/4885LMNA 3435/4885HPGD 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.